Simplifying Global Compliance
FDAnews Drug Daily Bulletin
SCOTUS Denies Classen Review, Sustains Safe Harbor Spat
Feb. 11, 2013
The U.S. Supreme Court Jan. 14 denied a petition by GlaxoSmithKline (GSK) to review a patent infringement case it hoped would expand Hatch-Waxman’s safe-harbor provisions to the company’s benefit. The Federal Circuit ruled in GSK v. Classen Immunotherapies that GSK was not protected in using Classen’s patents for vaccination scheduling methods during postmarket safety studies.
Clinical Trials Advisor
Copyright ©2019. All Rights Reserved.
Design, CMS, Hosting & Web Development :: ePublishing